+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of oral brepocitinib in adults with lichen planopilaris, a condition affecting the scalp. This Phase 23 trial aims to understand how well this medication works compared to a placebo in treating active and symptomatic lichen planopilaris. The study is sponsored by Priovant Therapeutics, Inc. and uses a randomized, double-blind design to ensure reliable results. Participants are randomly assigned to receive either oral brepocitinib or a placebo. The study is conducted in parallel groups, with neither the participants nor the researchers knowing who receives the active drug or placebo. The treatment period lasts 24 weeks, during which the participants take the assigned oral medication. The main goal is to measure improvement in the Investigator Global Assessment IGA score by Week 24. Throughout the study, participants will be regularly monitored for safety and symptom changes. Researchers will assess the proportion of participants who achieve significant improvement in their IGA scores at Week 24 and track changes in symptom severity using a numerical rating scale. The total study duration extends until July 2029, allowing for thorough evaluation of treatment effects and safety over time.

Age: 18Years +All GendersPhase 2Phase 3
61 locations
E

Actively Recruiting

Researchers are evaluating the effects of camoteskimab in adults aged 18 to 65 with moderate-to-severe atopic dermatitis. This phase 2b, multicenter, randomized, double-blind, placebo-controlled study aims to assess the efficacy and safety of camoteskimab compared to placebo. Participants include those who are treatment-naive or have had an inadequate response to previous biologic therapies. The study has two parts Part 1 is a 24-week placebo-controlled period where participants are randomly assigned to one of three camoteskimab dose levels or placebo, all administered by subcutaneous injection. In Part 2, an extension period, all participants receive camoteskimab. This design allows comparison of different dose levels and monitoring of long-term treatment effects. Participants will be assessed regularly throughout the study with measures including the Eczema Area and Severity Index EASI, Investigator Global Assessment IGA, and peak pruritus numerical rating scale PP-NRS. Safety and efficacy will be monitored through these assessments over 24 weeks and beyond. The study includes signing informed consent and adherence tracking, with the primary outcome focused on percentage change in EASI score from baseline to Week 24.

Age: 18Years - 65YearsAll GendersPhase 2
85 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of D-2570 in adults with moderate to severe plaque psoriasis. This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to assess how well D-2570 works and how safe it is for participants with this skin condition. The study focuses on participants who have had stable disease without major flares for at least six months. Participants will be randomly assigned to receive either a low dose or a high dose of D-2570 tablets, or placebo tablets that look identical. Treatments are given over a 12-week period, during which participants and researchers will monitor their responses to the study drug or placebo. The study uses a quadruple-blind design where participants, care providers, investigators, and outcome assessors do not know which treatment is given. During the study, participants will undergo various assessments including measurement of psoriasis severity using the Psoriasis Area and Severity Index PASI, Physicians Global Assessment PGA, and evaluation of body surface area affected. The primary outcome is improvement in PASI-90 after 12 weeks of treatment or placebo. Laboratory tests and safety monitoring will also be performed throughout the study to track any changes and ensure participant safety.

Age: 18Years - 70YearsAll GendersPhase 2
20 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness and long-term safety of PP405, a medicated topical gel, for treating Androgenetic Alopecia in adult males aged 18 to 55. This phase 23 randomized, double-blind study involves men who have experienced hair loss for at least six months and have specific severity scores on the Norwood-Hamilton scale. Participants are randomly assigned to receive either PP405 topical gel or a non-medicated vehicle gel applied to the scalp once daily for 24 weeks. After this initial period, those on PP405 continue the treatment while participants initially on the vehicle are re-randomized to either PP405 or vehicle for an additional 28 weeks, creating a total treatment duration of 52 weeks to assess both efficacy and safety over time. Throughout the study, participants will be regularly assessed for changes in hair count and scalp coverage using both clinical and participant evaluations at weeks 12 and 24. Safety monitoring continues during the extension phase up to week 52. The primary outcome focuses on the change in non-vellus target area hair count at week 24, with secondary measures including participant assessments of scalp coverage and hair count improvements at weeks 12 and 24.

Age: 18Years - 55YearsMALEPhase 2Phase 3
63 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis. This study aims to determine if ENV-294 impacts the severity and affected area of atopic dermatitis and to observe any medical problems participants may experience while taking the drug. Participants will be randomly assigned to receive either ENV-294 or a placebo once daily by mouth for 12 weeks. They will visit the clinic every 2 to 4 weeks for checkups and tests during this period. The study includes keeping a diary of symptoms and medication intake and concludes with a final clinic visit around week 16. During the trial, participants will undergo clinical assessments to evaluate the severity and extent of their skin condition, including scores such as vIGA and EASI. Safety monitoring involves tracking adverse events and laboratory tests. Researchers will also assess pharmacokinetics and patient-reported outcomes. The total participation spans about 16 weeks, covering treatment and follow-up visits.

Age: 18Years - 75YearsAll GendersPhase 2
32 locations
S

Actively Recruiting

This research aims to assess the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have severe alopecia areata, characterized by 50% or greater scalp hair loss. The study includes a double-blind, randomized, placebo-controlled treatment phase followed by an open-label extension. The goal is to better understand how well deuruxolitinib works and how safe it is for this age group with significant hair loss. Participants will be randomly assigned to receive either deuruxolitinib tablets or matching placebo tablets taken orally twice daily for 24 weeks during the initial treatment period. Following this, all participants will have the opportunity to receive deuruxolitinib for an additional 52 weeks in an open-label extension phase. This design allows comparison of the drug to placebo and longer-term evaluation of the drugs effects. Throughout the study, participants will have regular assessments of their hair loss using the Severity of Alopecia Tool SALT at multiple time points up to week 24 and beyond. Safety will be closely monitored by tracking side effects, vital signs, heart tests, lab results, and physical exams. Additional measurements include patient and clinician impressions of improvement, quality of life, and mental health assessments. The total study duration can extend up to 76 weeks of treatment plus safety follow-up to fully evaluate outcomes and tolerability.

Age: 12Years - 17YearsAll GendersPhase 3
64 locations